Getting Up to Speed on HCV Therapies

In this video module, Sherilyn C. Brinkley, MSN, CRNP; Elizabeth K. Goacher, PA-C, MHS; Jennifer Katzianer, PharmD, BCPS; and Andrew J. Muir, MD, discuss a multidisciplinary approach to the use of current HCV therapies and best practices in pretreatment, on-treatment, and posttreatment care for patients undergoing treatment for HCV infection.
Andrew J. Muir, MD
Program Director
Sherilyn C. Brinkley, MSN, CRNP
person default
Elizabeth K. Goacher, PA-C, MHS
Jennifer Katzianer, PharmD, BCPS
Physicians: maximum of 1.5 AMA PRA Category 1 Credits
Registered Nurses: 1.5 Nursing contact hours
Pharmacists: 1.5 contact hours (0.15 CEUs)
Physician Assistants: maximum of 1.5 hours of AAPA Category I (Preapproved) credits
Released: March 31, 2016 Expiration: March 30, 2017

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Counsel patients and coworkers regarding considerations that may influence the individualized choice among available all-oral therapies for patients with hepatitis C
  • Develop pretreatment support plans for patients awaiting hepatitis C treatment
  • Formulate on-treatment and posttreatment management strategies to support adherence, promptly detect and manage adverse events, and maximize opportunity for cure

Information on this Educational Activity

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Program Director

Andrew J. Muir, MD

Chief, Division of Gastroenterology
Associate Professor of Medicine
Department of Medicine
Director, Gastroenterology/Hepatology Research
Duke Clinical Research Institute
Duke University School of Medicine
Durham, North Carolina

Andrew J. Muir, MD, has disclosed that he has received funds for research support from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Roche and consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Janssen, Merck, and Theravance.

Faculty

Sherilyn C. Brinkley, MSN, CRNP

Clinical Practitioner
Program Manager,
Viral Hepatitis Center
Division of Infectious Disease
Department of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland

Sherilyn C. Brinkley, MSN, CRNP, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck and fees for non-CME/CE services from AbbVie, Bristol-Myers Squibb, and Gilead Sciences.
Elizabeth K. Goacher, PA-C, MHS

Lead Advanced Practice Provider
Division of Gastroenterology
Department of Medicine
Duke University
Durham, North Carolina

Elizabeth K. Goacher, PA-C, MHS, has disclosed that she has received consulting fees from AbbVie, Bristol-Myers Squibb, Gilead Sciences, Intercept, and Merck and fees for non-CME/CE services from AbbVie, Bristol-Myers Squibb, Gilead Sciences, and Merck.
Jennifer Katzianer, PharmD, BCPS

Clinical Coordinator
Johns Hopkins Home Care Group
Baltimore, Maryland

Jennifer Katzianer, PharmD, BCPS, has no real or apparent conflicts of interest to report.

Staff

Jenny Schulz, PhD

Director, Scientific Services

Jenny Schulz, PhD, has no real or apparent conflicts of interest to report.
Elaine P. Seeskin

Editorial Contributor

Elaine P. Seeskin has no real or apparent conflicts of interest to report.
Ryan P. Topping, PhD

Associate Managing Editor

Ryan P. Topping, PhD, has no real or apparent conflicts of interest to report.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN and Jan Schultz, RN, MSN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended for nurse practitioners, physician assistants, pharmacists, and other healthcare professionals involved in the care of patients with chronic hepatitis C.

Goal

The goal of this activity is to improve participants’ competence in using all-oral regimens to achieve cure in patients with chronic hepatitis C.

Physician Continuing Medical Education

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Credit Designation

This educational activity for 1.5 contact hours is provided by Postgraduate Institute for Medicine.

Accreditation Statement

Postgraduate Institute for Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Pharmacist Continuing Education

Accreditation Statement

Postgraduate Institute for Medicine is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Postgraduate Institute for Medicine designates this continuing education activity for 1.5 contact hour(s) (0.15 CEUs) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number - 0809-9999-16-273-H01-P)

Type of Activity:

Knowledge

Physician Assistant Continuing Education

Credit Designation

This program has been reviewed and is approved for a maximum of 1.50 hours of AAPA Category 1 CME credit by the Physician Assistant Review Panel. Approval is valid for one year from the issue date of 05/01/2016. Participants may submit at any time during that period.

Accreditation Statement

This program was planned in accordance with AAPA's CME Standards fir Enduring Material Programs and for Commercial Support of Enduring Material Programs.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from March 31, 2016, through March 30, 2017:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

Specifically for primary care: CCO slides from Jasmohan Bajaj, MD, and Terry Box, MD on common pitfalls in hepatic encephalopathy.

Jasmohan S. Bajaj, MD Terry D. Box, MD Released: January 14, 2020

Expert commentary from CCO on how providers can act as advocates for increased access to HCV care for persons who use drugs and incarcerated individuals

Oluwaseun Falade-Nwulia, MBBS, MPH Released: December 18, 2019

Watch this CME/MOC-certified video from a live symposium for expert guidance on approaches to improve diagnosis and treatment of HCV, HBV, and NASH.

Paul Y. Kwo, MD
Program Director
Manal F. Abdelmalek, MD, MPH Oluwaseun Falade-Nwulia, MBBS, MPH
Physicians: maximum of 1.5 AMA PRA Category 1 Credits US Physicians: maximum of 1.5 Medical Knowledge MOC point(s) Released: December 17, 2019 Expiration: December 16, 2020

CCO faculty Paul Kwo, MD, answers FAQs in hepatitis B management including treatment candidacy and duration

Paul Y. Kwo, MD
Program Director
Released: December 4, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?